{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:23:09Z","timestamp":1787840589571,"version":"build-2784847793"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hydroxyurea therapy is crucial in managing sickle cell disease (SCD) in pediatric patients, significantly reducing vaso-occlusive events. However, it is associated with hematological adverse drug reactions (HADRs), necessitating comprehensive evaluation to ensure patient safety and treatment optimization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The primary goal of our study is to investigate the prevalence, causality, severity, preventability, and predictability of HADRs associated with hydroxyurea therapy in pediatric patients with SCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A prospective observational study was conducted, involving 207 pediatric SCD patients undergoing hydroxyurea therapy. Data were collected from medical records and adverse drug reaction reporting forms. Causality, severity, preventability, and predictability assessments were conducted using standardized tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The prevalence of HADRs was 7.24%, with neutropenia (2.41%) and thrombocytopenia (1.93%) being the most common. Gender-specific prevalence rates, age distribution, and in-patient versus out-patient settings showed consistent patterns. Causality assessment revealed a high proportion of probable or certain HADRs. The majority of HADRs were of mild to moderate severity and considered preventable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Finding:<\/jats:title>\n                    <jats:p>Hydroxyurea therapy in pediatric SCD patients is associated with manageable HADRs, emphasizing the importance of pharmacovigilance for patient safety and treatment compliance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study offers significant insights into the prevalence, clinical management, and outcomes of HADRs associated with hydroxyurea therapy in pediatric SCD patients. The findings underscore the need for proactive management approaches to optimize treatment outcomes and ensure patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_482_24","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T10:00:20Z","timestamp":1750327220000},"page":"6-13","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Observational Study on Hematological Adverse Drug Reactions (HADRs) from Hydroxyurea in Pediatric Patients with Sickle Cell Disease (SCD): Assessing Prevalence, Causality, Severity, Preventability, and Predictability, along with Clinical Management by a Clinical Pharmacist at a Tertiary Care Teaching Hospital"],"prefix":"10.4103","volume":"17","author":[{"given":"Rajesh","family":"Hadia","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipika","family":"Bhil","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, SBKS Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"issue":"4 Suppl","key":"R2-20260422","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S.","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"R3-20260422","first-page":"1260","article-title":"Sickle cell disease in children: Differentiating osteomyelitis from vaso-occlusive crisis","volume":"28","author":"Lebensburger","year":"2012","journal-title":"Pediatr Emerg Care"},{"key":"R4-20260422","first-page":"64","article-title":"Hospital prevalence and clinical presentation of sickle cell syndrome among children under 5 years at a referral hospital in the Democratic Republic of Congo","volume":"43","author":"Kingwengwe","year":"2022","journal-title":"Pan Afr Med J"},{"key":"R5-20260422","first-page":"E118","article-title":"Prevalence of sickle cell disease in the United States","volume":"98","author":"Musallam","year":"2023","journal-title":"Am J Hematol"},{"key":"R6-20260422","first-page":"26","article-title":"Sickle cell disease: Part I: Epidemiology, pathophysiology, pain management, and nonpharmacological intervention","volume":"111","author":"Wang","year":"2011","journal-title":"Am J Nurs"},{"key":"R7-20260422","first-page":"297","article-title":"Sickle cell gene in the eastern and southern regions of Saudi Arabia","volume":"14","author":"Al-Qurashi","year":"2008","journal-title":"East Mediterr Health J"},{"key":"R8-20260422","first-page":"13","article-title":"Use of hydroxyurea in sickle cell disease: Reduction of recurrent and severe adverse drug reactions","volume":"104","author":"Tripathi","year":"2011","journal-title":"South Med J"},{"key":"R9-20260422","first-page":"858","article-title":"Hydroxyurea therapy in children severely affected with sickle cell disease","volume":"130","author":"Rogers","year":"1997","journal-title":"J Pediatr"},{"key":"R10-20260422","first-page":"e27005","article-title":"ydroxyurea use in children with sickle cell anemia: Toxicity, adherence, and efficacy in a Brazilian cohort","volume":"65","author":"Rodriguez","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia","volume":"74","author":"Platt","year":"1984","journal-title":"J Clin Invest"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"R13-20260422","first-page":"4421","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH)","volume":"117","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"e27228","DOI":"10.1002\/pbc.27228","article-title":"Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood","volume":"65","author":"Hankins","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/pbc.25705","article-title":"Hydroxyurea therapy for sickle cell anemia in sub-Saharan Africa: Rationale and experience in the design of the REACH trial","volume":"63","author":"McGann","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20260422","first-page":"788","article-title":"Persons with sickle cell disease have a significantly greater likelihood of recurrent and severe adverse drug reactions compared to those with other chronic diseases: A companion study to the multicenter investigation of hydroxyurea","volume":"58","author":"Lebensburger","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1056\/NEJM199004123221504","article-title":"Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea","volume":"322","author":"Rodgers","year":"1990","journal-title":"N Engl J Med"},{"key":"R19-20260422","first-page":"718","article-title":"Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia","volume":"127","author":"Wang","year":"2011","journal-title":"Pediatrics"},{"key":"R20-20260422","first-page":"437","article-title":"Adverse drug events during AKI and its recovery","volume":"10","author":"Smith","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R21-20260422","first-page":"520","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"18","author":"Rothman","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_482_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:25:35Z","timestamp":1787837135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_482_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_482_24","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-04-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}